Quince Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands except share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $21,813 | $20,752 |
| Short-term investments | 46,010 | 54,307 |
| Prepaid expenses and other current assets | 2,616 | 2,381 |
| Total current assets | 70,439 | 77,440 |
| Property and equipment, net | 234 | 234 |
| Operating lease right-of-use assets | 576 | 385 |
| Goodwill | 17,245 | 17,625 |
| Intangible asset | 62,253 | 63,672 |
| Other assets | 8,467 | 8,466 |
| Equity investments in Lighthouse Pharmaceuticals, Inc. | 78 | 78 |
| Total assets | $159,292 | $167,900 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 2,070 | $2,033 |
| Short-term contingent consideration | 4,748 | 4,103 |
| Accrued expenses and other current liabilities | 3,020 | 3,436 |
| Total current liabilities | 9,838 | 9,572 |
| Long-term debt | 13,518 | 13,429 |
| Long-term operating lease liabilities | 480 | 321 |
| Long-term contingent consideration | 55,503 | 53,603 |
| Deferred tax liabilities | 5,177 | 5,304 |
| Other long-term liabilities | 599 | 587 |
| Total liabilities | 85,115 | 82,816 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 authorized, (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | — | — |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 43,215,233 and 42,973,215 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively. | 43 | 43 |
| Additional paid in capital | 403,102 | 401,638 |
| Accumulated other comprehensive income | 1,825 | 3,047 |
| Accumulated deficit | (330,793) | (319,644) |
| Total stockholders’ equity | 74,177 | 85,084 |
| Total liabilities and stockholders’ equity | $159,292 | $167,900 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.